Free radicals in Alzheimer's dementia: Currently available therapeutic strategies

Journal of Neural Transmission, Supplement

Volumn , Issue 54, 1998, Pages 211-219

  Rosler M ^a   Retz, W ^a   Thome, J ^a   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; GINKGO BILOBA EXTRACT; RETINOL; SCAVENGER; SELEGILINE; TENILSETAM; CEDEMIN; FREE RADICAL; HERBACEOUS AGENT; MONOAMINE OXIDASE INHIBITOR; PIPERAZINE DERIVATIVE; PSYCHOTROPIC AGENT; THIOPHENE DERIVATIVE; VITAMIN;

ALZHEIMER DISEASE; DEMENTIA; DRUG EFFICACY; DRUG RESEARCH; HUMAN; NEUROPROTECTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; DRUG EFFECT; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; DRUGS, CHINESE HERBAL; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEURONS; PARKINSON DISEASE; PIPERAZINES; PSYCHOTROPIC DRUGS; SELEGILINE; THIOPHENES; VITAMINS;

EID: 0031593608     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7508-8_21     Document Type: Review

References (52)

1. Agnoli A, Martucci N, Fabbrini G, Buckley A, Fioravanti M (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109-114
2. Agnoli A, Fabbrini G, Fioravanti M, Martucci N (1992) CBF and cognitive evaluation of Alzheimer type patients before and after MAO-B treatment: a pilot study. Eur Neuropharm 2: 31-35
3. Bell J, Beglan C, London E (1996) Interaction of ascorbic acid with the neurotoxic effects of NMDA and sodium nitroprusside. Life Sci 58: 367-371
4. Burke W, Ranno A, Roccaforte W, Wengel S, Bayer B, Willcockson N (1993a) L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 41: 367-370
5. Burke W, Roccaforte W, Wengel S, Bayer B, Ranno A, Willcockson N (1993b) L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41: 1219-1225
6. Burns A, Marsh A, Bender D (1989) A trial of vitamin supplementation in senile dementia. Int J Ger Psychiat 4: 333-338
7. Burton G, Ingold K (1989) Vitamin E as an in vitro and vivo antioxidant. Ann NY Acad Sci 570: 7-21
8. Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus 1-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther 12: 306-3314
9. Frei B, England L, Ames B (1989) Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci 86: 6377-6381
10. Frölich I, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 45: 443-446
11. Falsaperla A, Monici Preti PA, Oliani C (1990) Selegiline versus oxiracetam in patients with Alzheimer's type dementia. Clin Ther 12: 376-384
12. Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32: 128-132
13. Finali G, Piccirilli M, Oliani C, Piccinin GL (1991) L-deprenyl therapy improves verbal memory in amnestic Alzheimer patients. Clin Neuropharm 14: 523-536
14. Finali G, Piccirilli M, Oliani C, Piccinin GL (1992) Alzheimer-type dementia and verbal memory performance: influence of selegiline therapy. Ital J Neurol Sci 13: 141-148
15. 2· free radicals. In: Christen Y, Courtois Y, Droy-Lefaix MT (eds) Advances in gingko biloba research. Elsevier, Paris
16. Gerlach M, Riederer P, Youdim M (1995) Neuroprotective therapeutic strategies. Biochem Pharmacol 50: 1-16
17. Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM (1991) The use of selegeline in Alzheimer's patients with behavior problems. J Clin Psychiat 52: 342-345
18. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1965) Decreased catalase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216-1223
19. Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623
20. Hennekens C, Buring J, Peto R (1994) Antioxidant vitamins -benefits not yet proved. N Engl J Med 330: 1080-1081
21. Herrschaft H (1992) Zur klinischen Anwendung von Gingko biloba bei dementiellen Syndromen. Pharmazie in unserer Zeit 21: 266-275
22. Hofferberth B (1994) The efficacy of Egb 761 in patients with senile dementia of the Alzheimer type, a double blind, placebo-controlled study on different levels of investigation. Hum Psychopharmacol 9: 215-222
23. Hopfenmüller W (1994) Nachweis der therapeutischen Wirksamkeit eines Gingko biloba-Spezialextraktes. Drug Res 44: 1005-1013
24. Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [PD-Sect] 1: 84-85
25. Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796-798
26. Kanowski S, Herrmann WM, Staphan K, Wierich W, Hörr R (1996) Proof of efficacy of the Gingko biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer Type or multi-infarct dementia. Pharmacopsychiatry 29: 47-56
27. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Donnell Lingle D, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521
28. Kleijnen J, Knipschild P (1992) Gingko biloba. Lancet 340: 1136-1139
29. +-treated dopaminergic neurons. Eur J Pharmacol 269: R3-R4
30. Lawlor B, Aisen P, Green C, Fine E, Schmeidler J (1997) Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. Int J Ger Psychiat 12: 319-322
31. Liebler D (1993) Antioxidant reactions of carotenoids. Ann NY Acad Sci 691: 20-31
32. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 31: 100-107
33. Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G (1991) Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer's type. Influence of treatment with 1-deprenyl. J Neural Transm [PD-Sect] 3: 15-25
34. Meydani M (1995) Vitamin E. Lancet 345: 170-174
35. Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315-322
36. Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm [PD-Sect] 8: 193-208
37. Münch G, Simm A, Double KL, Riederer P (1996) Commentary: oxidative stress and advanced glycation endproducts - parts of a vicious circle of neurodegeneration. Alzheimer's Dis Rev 1: 71-74
38. Packer L, Haramaki N, Kawabata T, Marcocci L, Maitra I, Maguire JJ, Droy-Lefaix MT, Sebaki AH, Gardes-Albert M (1995) Gingko biloba extract (Egb 761): antioxidant action and prevention of oxidative stress-induced injury. In: Christen Y, Courtois Y, Droy-Lefaix MT (eds) Advances in Gingko biloba research, vol 4. Elsevier, Paris
39. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176-183
40. Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bordin A, Crepaldi G, Christiani G, Cucinotta D (1995) Posatireline for the treatment of late onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol Scand 92: 135-140
41. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE (1995) Trial of d-α-Tocopherol in Huntington's disease. Am J Psychiatry 152: 1771-1775
42. Piccinin GL, Final G, Piccirilli M (1990) Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia. Clin Neuropharm 13: 147-163
43. Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman C, Pfreifer E, Schneider L, Thal L (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
44. Schneider L, Pollo V, Zemansky M, Gleason R, Palmer R, Sloane B (1991) A pilot study of low-dose 1-deprenyl in Alzheimer's disease. J Ger Psychiat Neurol 4: 143-148
45. Schneider L, Olin J, Pawluczyk S (1993) A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 150: 321-323
46. Smith MA, Sayre L, Perry G (1996) Is Alzheimer's a disease of oxidative stress? Alzheimer's Dis Rev 1: 63-67
47. Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) Dose-dependent effects of deprenyl on CSF metabolites in patients with Alzheimer's disease. Psychopharmacology 91: 293-296
48. Tariot P, Cohen R, Sunderland T, Newhouse P, Yount D, Mellow A, Weingartner H, Mueller E, Murphy D (1987) L-deprenyl in Alzheimer's disease. Arch Gen Psychiatry 44: 427-433
49. Tariot P, Sunderland T, Weingartner H, Murphy D, Welkowitz J, Thompson K, Cohen R (1987) Cognitive effects of 1-deprenyl in Alzheimer's disease. Psychopharmacology 91: 489-495
50. Thome J, Gsell W, Rösler M, Kornhuber J, Frölich I, Hashimoto E, Zielke B, Wiesbeck G, Riederer P (1996) Oxidative stress associated parameters (lactoferrin, superoxide dismutase) in serum of patients with Alzheimer's disease. Life Sci 60: 13-19
51. Weitbrecht WU, Jansen W (1986) Primär degenerative Demenz: Therapie mit Gingko-biloba-Extrakt. Fortschr Med 104: 199-202
52. White HL, Scates P, Cooper BR (1996) Extracts of Gingko biloba leaves inhibit monoamine oxidase. Life Sci 58: 1315-1321